Research slowly catching up. Another few shots on goal added, published in the past 4 weeks and iPSC-MSCs:
Human induced pluripotent stem cell-derived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses
Abstract
The transplantation of mesenchymal stem cells (MSCs) has been a reported method for alleviating atherosclerosis (AS). Because the availability of bone marrow‑derived MSCs (BM‑MSCs) is limited, the authors used this study to explore the use of a new type of MSC, human induced pluripotent stem cell‑derived MSCs (iPSC‑MSCs), to evaluate whether these cells could alleviate AS. iPSC‑MSCs were intravenously administered to ApoE knock out mice fed on a high‑fat diet (HFD) for 12 weeks. It was reported that systematically administering iPSC‑MSCs clearly reduced the size of plaques. In addition, the numbers of macrophages and lipids in plaques were lower in the HFD + iPSC‑MSCs group than in the HFD group. Furthermore, iPSC‑MSCs attenuated AS‑associated inflammation by decreasing the levels of inflammatory cytokines, such as tumor necrosis factor‑α and interleukin‑6, in serum. In addition, the expression of Notch1 was higher in the HFD group, and injecting iPSC‑MSCs reversed this effect. In conclusion, the current study provides the first evidence indicating that iPSC‑MSCs may be a new optional MSC‑based strategy for treating AS.
https://www.spandidos-publications.com/10.3892/mmr.2017.8075
Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice
ABSTRACT
Human induced pluripotent stem cell-derived mesenchymal stem cells (iPS-MSCs) are emerging as attractive options for use in cell replacement therapy, but their effect in kidney diseases remains unknown. Here, we showed that intravenous injection of iPS-MSCs protect against renal function loss in both short-term and long-term models of adriamycin nephropathy (AN). In the short-term AN model, iPS-MSCs conferred a substantial anti-apoptotic effect on tubular cells, associated with a downregulation of Bax and Bax/Bcl2 ratio and an upregulation of survivin expression. In vitro, conditioned medium from iPS-MSCs (iPSMSC-CM) significantly limited albumin-induced tubular apoptosis and enhanced tubular proliferation, accompanied by a reduced expression of tubular Bax and an elevated expression of Bcl2 and survivin. Oxidative stress was markedly attenuated by iPS-MSCs both in AN mice and in protein-overloaded tubular cells. In the long-term AN model, repeated injections of iPS-MSCs significantly inhibited tubulointerstitial fibrosis and reduced intrarenal deposition of collagen I, collagen IV and αSMA. Modulation of the hedgehog signaling pathway contributed to the anti-fibrotic effect of iPS-MSCs in chronic AN. Finally, we detected that most of the infused iPS-MSCs were entrapped in the lungs. In conclusion, our data support a beneficial role of iPS-MSCs in both acute and chronic AN.
[...]
http://www.oncotarget.com/index.php...age=article&op=view&path[]=21760&path[]=69045
- Forums
- ASX - By Stock
- CYP
- roll out the news
roll out the news, page-300
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $35.20M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.5¢ | $1.705K | 8.654K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 12792 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 32500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 12792 | 0.195 |
4 | 126276 | 0.190 |
4 | 17855 | 0.180 |
2 | 5997 | 0.175 |
1 | 50000 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 32500 | 1 |
0.205 | 46000 | 1 |
0.210 | 60000 | 1 |
0.220 | 1875 | 1 |
0.240 | 10000 | 1 |
Last trade - 10.02am 30/08/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online